IL1B and ductal breast carcinoma in situ: Like IRIS [33], the expression of IL-1β is steadily increase from very low in normal breast epithelium, to relatively high in patients with ductal carcinoma in situ (DCIS), to even higher in patients with invasive ductal carcinoma (IDC) with no relapse, and is highest in patients with IDC with relapse [64].